Reuters Article: Barriers to Latest Alzheimer’s Treatments for Down Syndrome Community
Hampus Hillerstrom, CEO of LuMind IDSC Foundation and father to a child with Down syndrome, knows about the barriers people
October 10, 2023
Hampus Hillerstrom, CEO of LuMind IDSC Foundation and father to a child with Down syndrome, knows about the barriers people
Question: My brother is 60 years old with late stage Alzheimer’s Disease. He has begun experiencing the occasional sleepless night
LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published in The Boston Globe. Authors
Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC is working on many levels
LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease July 7, 2023 In a
Last week the FDA announced a full approval of a new drug called Leqembi to treat Alzheimer’s Disease. The approval
The guidebook linked below was published by the National Down Syndrome Society “to help empower families and caregivers with knowledge
People with Down syndrome have a high risk of developing Alzheimer disease dementia. However, penetrance and age at onset are
Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from accessing new therapies for Alzheimer’s
An international group of experts convened to determine prescribing criteria equivalences that would be inclusionary of adults with Down syndrome.